Clinical Trials for Non-Small Cell Lung Cancer

A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Eligible patients are adults with advanced or metastatic renal cell carcinoma, melanoma, cutaneous squamous cell carcinoma, or PD-L1-positive non-small cell lung cancer who are relapsed/refractory to standard therapy or lack standard options, have ECOG 0/1, and meet organ function criteria; exclusions include prior IL-2, active autoimmune disease, and symptomatic brain metastases requiring steroids. Treatments include WTX-124, a conditionally activated IL-2 prodrug that targets the tumor microenvironment, as monotherapy or in combination with pembrolizumab (anti-PD-1).

ClinicalTrials.gov ID: NCT05479812

A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with untreated, unresectable or metastatic non-squamous NSCLC harboring a KRAS G12C mutation and PD-L1 TPS <50%, evaluating the combination of adagrasib (a KRAS G12C inhibitor) with pembrolizumab and platinum-based chemotherapy. Patients must be naïve to prior KRAS G12C inhibitors and selected prior systemic therapies; those with active brain metastases are excluded.

ClinicalTrials.gov ID: NCT05609578

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with PD-L1 positive metastatic NSCLC who have progressed after prior PD-1/PD-L1 inhibitor and platinum chemotherapy (and without known targetable mutations), randomizing them to receive either acasunlimab (a bispecific PD-L1/4-1BB antibody) plus pembrolizumab or standard docetaxel.

ClinicalTrials.gov ID: NCT06635824

A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with metastatic or recurrent ALK fusion-positive NSCLC, including both those who are treatment-naïve and those previously treated with at least one second-generation ALK TKI, and evaluates the combination of lorlatinib (a third-generation ALK/ROS1 tyrosine kinase inhibitor with CNS activity) and ramucirumab (a VEGFR2 inhibitor targeting angiogenesis).

ClinicalTrials.gov ID: NCT06007937

Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced lung cancer (small cell or non-small cell), particularly those over 70 and/or with significant comorbidities or ECOG 0-3, who may not tolerate standard full-dose chemotherapy. Patients receive established cytotoxic chemotherapy regimens (such as platinum doublets or single agents), modified with prespecified reduced dosing based on age and comorbid health conditions.

ClinicalTrials.gov ID: NCT05800587

A Biomarker Study of Low-Dose IL-2 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously untreated, stage IV non-small cell lung cancer (adenocarcinoma or squamous) with tumor PD-L1 expression ≥1%, and tests pembrolizumab (anti-PD-1) combined with a 3-week course of low-dose IL-2 (aldesleukin, an immune modulator aimed at reinvigorating T cells), followed by pembrolizumab monotherapy. Patients with actionable driver mutations, prior systemic therapy, or active autoimmune disease are excluded.

ClinicalTrials.gov ID: NCT05493566

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors (including gastric, renal, melanoma, sarcoma, testicular germ cell, cervical, mesothelioma, NSCLC, or head and neck cancers) who have progressed after standard therapies, and investigates the investigational TNFR2 agonist antibody HFB200301 (stimulating anti-tumor immunity) as monotherapy or in combination with the anti-PD-1 antibody tislelizumab. Eligible patients must have measurable disease, ECOG 0-1, and no prior TNFR2-targeted therapy or active autoimmune disease.

ClinicalTrials.gov ID: NCT05238883

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with relapsed or metastatic solid tumors—particularly breast, ovarian, endometrial, biliary tract, and squamous NSCLC—who have received prior therapy, evaluating the antibody-drug conjugate AZD8205 (targets B7-H4 and delivers a topoisomerase I inhibitor) as monotherapy or in combination with the PD-1/TIGIT bispecific antibody rilvegostomig or the PARP inhibitor saruparib. Eligible patients must have measurable disease, ECOG 0-1, and adequate organ function, with some sub-studies focusing on select tumor types.

ClinicalTrials.gov ID: NCT05123482

Phase II Trial of the Addition of Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced EGFR-mutated (exon 19 deletion or L858R) non-small cell lung cancer who have developed oligoprogressive (1–5 extracranial sites) disease on first-line osimertinib monotherapy. All participants continue osimertinib (an EGFR tyrosine kinase inhibitor) and receive biologically guided radiation therapy (BgRT) and SBRT to progressive lesions.

ClinicalTrials.gov ID: NCT06014827

A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with metastatic or unresectable solid tumors (including NSCLC, HNSCC, HER2-negative breast, esophageal, cutaneous SCC, ovarian, bladder, cervical, pancreatic, and gastric cancers), evaluating the antibody-drug conjugate sigvotatug vedotin—targeting integrin beta-6—with or without pembrolizumab and/or platinum chemotherapy. Eligibility varies by cohort, including both treatment-naïve and previously treated/refractory patients, with fresh or recent tumor biopsy required in some arms.

ClinicalTrials.gov ID: NCT04389632